NDAORALTABLETPriority Review
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
38
Data completeness
4/8 — Partial
Priority Review
XIFAXAN (rifaximin) by Bausch Health. Approved for hepatic encephalopathy, travelers' diarrhea, diarrhea. First approved in 2010.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIFAXAN (rifaximin) is an oral antibiotic tablet approved by the FDA on March 24, 2010, and marketed by Bausch Health. Rifaximin is a non-systemic antibiotic with activity against gram-positive and gram-negative bacteria. The product is indicated for traveler's diarrhea and other gastrointestinal infections where local antibiotic activity is therapeutically beneficial. XIFAXAN represents a specialized niche in infectious disease treatment focused on enteric pathogens.
$1.1BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on XIFAXAN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.